Non Small Cell Lung Cancer Clinical Trials

204 studies are recruiting for non small cell lung cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 3

1. TOP 2301: Neoadjuvant Chemo for NSCLC

   This study was originally opened on 10/22/2024 as an open-label, two-arm, randomized phase 2 clinical trial, patients with clinical stage 1B-3A non-small cell lung cancer (NSCLC) to receive neoadjuvant chemotherapy and cemiplimab every 3 weeks for 3 cycles with or without alirocumab every 4 weeks p…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Duke University, Durham, North Carolina

   Run by

   Duke University

   See if you can join NCT06385262 on ClinicalTrials.gov

2. A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

   Researchers are investigating new treatments for untreated advanced non-small cell lung cancer (NSCLC), which is the most common form of lung cancer and lung cancer that has spread beyond surgical removal. Standard treatments include immunotherapy, such as pembrolizumab, and chemotherapy. This stud…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Kentucky ( Site 0019), Lexington, Kentucky

   Locations

   41 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06731907 on ClinicalTrials.gov

3. A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events, change in disease activity and pharmacokinetics of ABBV-253. ABBV-253 is an investigational drug being developed for the treatment of advanced solid…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Midwest /ID# 283487, Grand Rapids, Michigan

   Locations

   3 in total

   Run by

   AbbVie

   See if you can join NCT07807956 on ClinicalTrials.gov

4. Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

   This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute, Denver, Colorado

   Locations

   6 in total

   Run by

   ModeX Therapeutics, An OPKO Health Company

   See if you can join NCT06239194 on ClinicalTrials.gov

5. A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

   This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tirumotecan plus pembrolizumab is superior to pembrolizumab mon…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   UAMS Winthrop P. Rockefeller Cancer Institute ( Site 0060), Little Rock, Arkansas

   Locations

   270 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06312137 on ClinicalTrials.gov

6. A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

   This is a Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or metastatic NSCLC. The study will consist of several sub-studies, each evaluating the safety, tolerability, and preliminary antitumour activity of vario…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Research Site, Santa Monica, California

   Locations

   83 in total

   Run by

   AstraZeneca

   See if you can join NCT07098338 on ClinicalTrials.gov

7. Biomarkers for Risk Stratification in Lung Cancer

   This is a prospective observational study that will follow patients who undergo lung cancer screening at the San Francisco VA Medical Center, University of California, San Francisco (UCSF) Medical Center, and the San Francisco General Hospital. The proposed study will comprise of two primary popula…

   Stage

   Not phased

   Ages

   40 and older

   Site

   Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, California

   Locations

   3 in total

   Run by

   University of California, San Francisco

   See if you can join NCT03774758 on ClinicalTrials.gov

8. A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

   A phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to patients with locally advanced or metastatic HNSCC and to patients with any documented EGFR-mutant locally advanced or metastatic NSCLC.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Site 105 - START Los Angeles, Los Angeles, California

   Locations

   8 in total

   Run by

   EpiBiologics

   See if you can join NCT07462377 on ClinicalTrials.gov

9. TCR1188-ABC Cells in KRAS-mutated Cancers

   This is a Phase I, open-label dose finding study to assess the safety, manufacturing feasibility, and preliminary efficacy of TCR1188-ABC cells in patients with KRAS-mutated cancers. Initially, patients with KRAS G12V mutation positive metastatic pancreatic adenocarcinoma, cholangiocarcinoma, color…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Run by

   University of Pennsylvania

   See if you can join NCT07594067 on ClinicalTrials.gov

10. Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)

    This is a Phase II clinical study for people with stage IV cancer. The study will evaluate the use of stereotactic body radiation therapy (SBRT), a type of focused radiation treatment, together with immunotherapy-based treatment. SRBT will be used to treat multiple areas of cancer that have spread …

    Stage

    Phase 2

    Ages

    18 to 99

    Site

    University of Kentucky Markey Cancer Center, Lexington, Kentucky

    Run by

    Mark Bernard

    See if you can join NCT07770100 on ClinicalTrials.gov

11. A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

    This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of California Los Angeles - Jonsson Comprehensive Cancer Center, Los Angeles, California

    Locations

    38 in total

    Run by

    Genentech, Inc.

    See if you can join NCT04302025 on ClinicalTrials.gov

12. Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

    The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved, on-label systemic therapy utilizing immune checkpoint inhib…

    Stage

    Phase 3

    Ages

    18 to 100

    Site

    Hoag Memorial Hospital Presbyterian, Newport Beach, California

    Locations

    16 in total

    Run by

    InSightec

    See if you can join NCT05317858 on ClinicalTrials.gov

13. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

    BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The stu…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Banner Health- MD Anderson Cancer Center, Gilbert, Arizona

    Locations

    49 in total

    Run by

    Institut de Recherches Internationales Servier

    See if you can join NCT05786924 on ClinicalTrials.gov

14. A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

    The main purpose of this study is to evaluate the efficacy of divarasib compared with investigator's choice of immunotherapy (pembrolizumab or nivolumab) or observation in participants with resected Kirsten rat sarcoma viral oncogene homolog glycine 12 to cysteine (KRAS G12C)-positive Stage II-IIIB…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Community Cancer Institute (CCI), Clovis, California

    Locations

    46 in total

    Run by

    Hoffmann-La Roche

    See if you can join NCT07541170 on ClinicalTrials.gov

15. Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow

    Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery. Also, early detection of lung cancer with low dose CT screening may cure patients at an early stage. Circulating and disseminated…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Harry S Truman Veterans Memorial Hospital, Columbia, Missouri

    Run by

    University of Missouri-Columbia

    See if you can join NCT03551951 on ClinicalTrials.gov

16. Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

    A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

    Stage

    Phase 2

    Ages

    18 and older

    Site

    UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care building, Irvine, California

    Locations

    187 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT07100080 on ClinicalTrials.gov

17. Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

    The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients aged ≥ 18 years with solid tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    United Theranostics, Princeton, New Jersey

    Locations

    9 in total

    Run by

    Novartis Pharmaceuticals

    See if you can join NCT07261631 on ClinicalTrials.gov

18. A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

    A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Grand Rapids, Michigan

    Locations

    13 in total

    Run by

    AstraZeneca

    See if you can join NCT07115043 on ClinicalTrials.gov

19. Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-small cell lung cancer (NSCLC) that is either locally advanced…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Pioneer Research Center, Bullhead City, Arizona

    Locations

    484 in total

    Run by

    Pfizer

    See if you can join NCT07222566 on ClinicalTrials.gov

20. Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

    This study is being done to learn more about a new medicine called PF-08634404 and how it works when used with other cancer medicines in people who have advanced solid tumors. An advanced solid tumor is a type of cancer that has spread beyond its original location and cannot be removed by surgery o…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Highlands Oncology Group, PA, Fayetteville, Arkansas

    Locations

    104 in total

    Run by

    Pfizer

    See if you can join NCT07227298 on ClinicalTrials.gov

21. Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

    This study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well it works when given alone or with chemotherapy. The study is for adults with early stage or locally advanced non-small cell lung cancer (NSCLC) that may or may not be removabl…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Clearview Cancer Institute (Crestwood), Huntsville, Alabama

    Locations

    37 in total

    Run by

    Pfizer

    See if you can join NCT07489066 on ClinicalTrials.gov

22. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

    This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    USOR HonorHealth, Phoenix, Arizona

    Locations

    66 in total

    Run by

    Genmab

    See if you can join NCT05579366 on ClinicalTrials.gov

23. A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

    The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of single-agent divarasib or combined with other anti-cancer therapies in participants with previously untreated, advanced or metastatic non-small cell lung cancer (NSCLC).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Yale Cancer Center, New Haven, Connecticut

    Locations

    71 in total

    Run by

    Hoffmann-La Roche

    See if you can join NCT05789082 on ClinicalTrials.gov

24. A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

    The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Alaska Oncology and Hematology, Anchorage, Alaska

    Locations

    288 in total

    Run by

    Hoffmann-La Roche

    See if you can join NCT06793215 on ClinicalTrials.gov

25. Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

    Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites. I) After lead in of 10 patients demonstrating safety of treatment, allow for expansion…

    Stage

    Phase 1

    Ages

    18 to 99

    Site

    Banner MD Anderson Cancer Center, Gilbert, Arizona

    Locations

    3 in total

    Run by

    University of Arizona

    See if you can join NCT06814496 on ClinicalTrials.gov